På grund af risiko for øget systemisk absorption af pimecrolimus, kan {(Sær) navn} ikke anbefales til patienter med Nethertons syndrom.
Due to the potential for increased systemic absorption of pimecrolimus, < Invented Name > is not recommended in patients with Netherton's syndrome.